03-278US1 Ø

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.:

Weenna Bucay-Couto et al. 10/664,601

Date Filed:

09/18/2003

Title:

SOLID OR SEMI-SOLID THERAPEUTIC FORMULATIONS

Group Art Unit:

Examiner .: Atty. Docket:

Thurman K. Page

03-278US1

INFORMATION DISCLOSURE STATEMENT (IDS)

Mail Stop Amendment **Commissioner For Patents** P.O. Box 1450 Alexandria, VA 22313-1450

SIR:

In accordance with 37 C.F.R. §1.56 and in compliance with 37 C.F.R. §§1.97 and 1.98, the references listed on attached Form PTO/SB/08 and/or subsequently identified herein, are being submitted herewith for consideration by the United States Patent and Trademark Office.

I.	COPIES a.⊠ b.□	A legible copy of (i) ea caused it to be listed; and listed, is included herewit Any patents, publications not enclosed herewith we	ch foreign patent; (ii) each public (iii) all other information or that ph. or other information which are list ere previously cited by or submitted hich has been relied upon for an	ortion which caused it to be ed on PTO/SB/08 which are ed to the PTO in one of the
		U.S. Serial Number		U.S. Filing Date
II.	CONCIS a. ⊠ b. □ c. □	Except as may be indicated other information are in the A concise explanation of listed that is not in the English	HE RELEVANCE (check at least of below in (b) of this section, all of the English language (concise expland the relevance of all patents, publication is provided for the Example 1.	f the patents, publications or ation not required). cations or other information
III. 🗌	The Exa	y be related to the prese	ED APPLICATION(S) following co-pending application(nt application. By bringing this does(do) not waive the confidentia	(these) applications to the
	Serial N	<u>o.</u>	Filing Date	Art Unit

Docket: 03-278US1

FEES

IV. 🛛	THIS II	OS IS BEING FILED UNDER 37 C.F.R. §1.97(b): (check one box)
	a. 🗌	within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d) (37 C.F.R. §1.97(b)(1)). No fee or statement is required.
	b. <u> </u>	within three months of the date of entry of the national stage as set forth in § 1.491 in an
	c. 🛛	international application (37 C.F.R. §1.97(b)(2)). No fee or statement is required. before the mailing date of a first Office Action on the merits (37 C.F.R. §1.97(b)(3)). No fee or statement is required.
	d.□	before the mailing date of a first Office Action after the filing of a request for continued examination under § 1.114 (37 C.F.R. § 1.97(b)(4)). No fee or statement is required.
v. 🗆	before t	OS IS BEING FILED UNDER 37 C.F.R. §1.97(c): (check one box) the mailing date of any of a Final Office Action under 37 C.F.R. §1.113, a Notice of the under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in the ion (See 37 C.F.R. §1.97(c)). No statement; therefore, charge deposit account 50-1047 the fee set forth in 37 C.F.R. §1.17(p). See the statement below. No fee is required.
VI.		OS IS BEING FILED UNDER 37 C.F.R. §1.97(d):
	on or be	a statement under 37 C.F.R. §1.97(e) as provided below; and
	2)	charge deposit account 50-1047 the petition fee set forth in §1.17(p).
VII. 🗌		MENT UNDER 37 C.F.R. §1.97(e) (check only one box, if applicable) dersigned hereby states that each item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months
	b. 🗌	prior to the filing of IDS; or no item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application, and to knowledge of the person signing the statement after making reasonable inquiry, no item of information contained in the IDS was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of this statement, or
	c.	some of the items of information contained in the IDS were cited in a communication from a foreign Patent Office. As to this information, the undersigned states that each item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby states that no item of this remaining information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application or, to the knowledge of the person signing the statement after making reasonable inquiry, no item of information contained in the IDS was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of this statement.
VIII.	PAYM	ENT OF FEES
		A check in the amount of is enclosed for the above-identified fee(s). Please charge Deposit Account No. 50-1047 in the amount of \$180.00 for the above-indicated fee(s).
	\boxtimes	If Applicant has overlooked any additional fees, or if any overpayment has been made, the Commissioner is hereby authorized to credit or debit Deposit Account 50-1047.
		Two Copies of this paper are attached for Deposit Account charges and debits.

Docket: 03-278US1

It is Applicant(s)' opinion that the claims presently on file patently distinguish the present invention from each of these references. The above references are being cited only in the interests of candor and without any admission that they constitute statutory prior art or contain matter which anticipates the invention or which would render the same obvious, either singly or in a combination, to a person of ordinary skill in the art.

If the Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule (with a petition if necessary) and charge the appropriate fee to Deposit Account No. 50-1047.

Respectfully submitted,

Keum J. Park Reg. No. 42,059 Attorney for Applicant(s)

MAYER FORTKORT & WILLIAMS Customer Number 27774

> Tel. 908-518-7700 518-7795

		Fax 908-5
Enclosures:	\boxtimes	PTO/SB/08
	\boxtimes	References (excluding U.S. patent documents)
		Foreign Search Report
		Other:

Certificate of Mailing by First Class Mail

Continuate of Manning of This Chass Man
I certify that this document and fee is being deposited with sufficient postage
with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 on
6/10/05
and is addressed to Mail Stop Amendment, Commissioner for Patents,
P.O. Box 1450, Alexandria, VA 22313-1450.
Majne Segnate
Signature of Person Mailing Correspondence
Marjorie Scariati

Typed or Printed Name of Person Mailing Certificate

Docket: 03-278US1

PTO/SB/O8A (10-96)

Approved for use through 10/31/99, OMB 0651-0031
Patent and Trademark Office: U.S./DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to a collection of information unless it contains a valid OMB control number.

o i apci	HOIN	reduction Act of	1000, 11	o persons are requi	ed to a conection of information diffe	ess it contains a valid Olvid Control Hulling	
Substitute for form 1449A/PTO					Complete if Known		
Capatitate for form 1440/01 10					Application Number	10/664,601	
11	NFC	RMATION	DISC	LOSURE	Filing Date	09/18/2003	
STATEMENT BY APPLICANT (use as many sheets as necessary)					First Named Inventor	Weenna Bucay-Couto	
					Group Art Unit	1615	
					Examiner Name	Thurman K. Page	
She	a t	1	of	1	Attorney Docket Number	03-278US1	

FREEDINET	Cite	U.S. Paten	Document	Name of Patentee or Applicant	Date of Publication of Cited Document
mitials*	No.	Number	Class/Subclass	of Cited Document	MM-DD-YYYY
	1	6,495,164 B1	424/489	Ramstack et al.	12-17-2002
	2	4,927,806 A	514/2	Kramer et al.	05-22-1990

Examiner Initials*	Cite No.	U.S. Patent Applications		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Class/Subclass	s	
	1	2003/064998 A1	514/259.41	Francois et al.	04-03-2003
				1	

Examiner	Cite	Foreign Patent Document			Name of Patentee or Applicant of	Date of Publication of	T
Initials*	No. ¹	Office ³	Number ⁴	Class/Subclass	Cited Document	Cited Document MM-DD-YYYY	
	1	EP	1 197 208 A1	A61K 9/52	Takeda Chemical Industries Ltd	04-17-2002	
	2	EP	1 078 636 A1	A61K 31/715	Zhao	02-28-2001	
	3	GB	811,717	A61k	Pfizer & Co., Inc.	04-08-1959	

Examiner	Date	
Signature	Considered	
3.3.13.13.13		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

12 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.